HC Wainwright Reaffirms Buy Rating for Evaxion Biotech A/S (NASDAQ:EVAX)

HC Wainwright reissued their buy rating on shares of Evaxion Biotech A/S (NASDAQ:EVAX – Free Report) in a report published on Wednesday, MarketBeat reports. HC Wainwright currently has a $14.00 price target on the stock. HC Wainwright also issued estimates for Evaxion Biotech A/S’s FY2024 earnings at ($0.01) EPS, FY2025 earnings at $0.13 EPS, FY2026 […]

Related Keywords

,Jpmorgan Chase Co ,Beacon Capital Management ,Nasdaq ,Elm Advisors ,Susquehanna International Group ,Ae Wealth Management ,Evaxion Biotech ,Free Report ,International Group ,Capital Management ,Get Free Report ,Evaxion Biotecha S ,Nasdaq Evax ,Devax ,Medical ,Reiterated Rating ,Hc Wainwright ,